Importance of highly selective LC-MS/MS analysis for the accurate quantification of tamoxifen and its metabolites: Focus on endoxifen and 4-hydroxytamoxifen

Breast Cancer Research and Treatment

Volumn 133, Issue 2, 2012, Pages 793-798

  Jager, N G L ^a   Rosing, H ^a   Linn, S C ^b   Schellens, J H M ^b,c   Beijnen, J H ^a,c  

^a SLOTERVAART HOSPITAL   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

4 Hydroxytamoxifen; Endoxifen; LC MS MS analysis; Metabolite levels; Tamoxifen

Indexed keywords

1,2 EPOXYTAMOXIFEN; AFIMOXIFENE; DROLOXIFENE; DRUG METABOLITE; ENDOXIFEN; HYDROXYTAMOXIFEN; NORTAMOXIFEN; TAMOXIFEN; UNCLASSIFIED DRUG;

ACCURACY; ARTICLE; DRUG BLOOD LEVEL; DRUG DETERMINATION; FRAGMENTATION REACTION; HUMAN; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MASS SPECTROMETRY; PRIORITY JOURNAL; SEPARATION TECHNIQUE;

ANTINEOPLASTIC AGENTS, HORMONAL; CHROMATOGRAPHY, LIQUID; HUMANS; TAMOXIFEN; TANDEM MASS SPECTROMETRY;

EID: 84863691662     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-012-2000-1     Document Type: Article

References (20)

1. Peng J, Sengupta S, Jordan VC (2009) Potential of selective estrogen receptor modulators as treatments and preventives of breast cancer. Anticancer Agents Med Chem 9(5):481-499
2. Shao W, Brown M (2004) Advances in estrogen receptor biology: prospects for improvements in targeted breast cancer therapy. Breast Cancer Res 6(1):39-52
3. Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S (2011) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378(9793):771-784
4. Johnson MD, Zuo H, Lee KH, Trebley JP, Rae JM, Weatherman RV (2004) Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat 85(2):151-159
5. Teunissen SF, Rosing H, Seoane MD, Brunsveld L, Schellens JHM, Schinkel AH, Beijnen JH (2011) Investigational study of tamoxifen phase I metabolites using chromatographic and spec-troscopic analytical techniques. J Pharm Biomed Anal 55(3): 518-526
6. Lim YC, Desta Z, Flockhart DA, Skaar TC (2005) Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen. Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estro-genic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen. Cancer Chemother Pharmacol 55(5): 471-478
7. Lu WJ, Desta Z, Flockhart DA (2012) Tamoxifen metabolites as active inhibitors of aromatase in the treatment of breast cancer. Breast Cancer Res Treat 131(2):473-481
8. Madlensky L, Natarajan L, Tchu S, Pu M, Mortimer J, Flatt SW, Nikoloff DM, Hillman G, Fontecha MR, Lawrence HJ, Parker BA, Wu AH, Pierce JP (2011) Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes. Clin Pharmacol Ther 89(5):718-725
9. Borges S, Desta Z, Li L, Skaar TC, Ward BA, Nguyen A, Jin Y, Storniolo AM, Nikoloff DM, Wu L, Hillman G, Hayes DF, Stearns V, Flockhart DA (2006) Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther 80(1):61-74
10. Murdter TE, Schroth W, Bacchus-Gerybadze L, Winter S, He-inkele G, Simon W, Fasching PA, Fehm T, Eichelbaum M, Schwab M, Brauch H (2011) Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma. Clin Pharmacol Ther 89(5):708-717
11. Barginear MF, Jaremko M, Peter I, Yu C, Kasai Y, Kemeny M, Raptis G, Desnick RJ (2011) Increasing tamoxifen dose in breast cancer patients based on CYP2D6 genotypes and endoxifen levels: effect on active metabolite isomers and the antiestrogenic activity score. Clin Pharmacol Ther 90(4):605-611
12. Gjerde J, Hauglid M, Breilid H, Lundgren S, Varhaug JE, Ki-sanga ER, Mellgren G, Steen VM, Lien EA (2008) Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism. Ann Oncol 19(1):56-61
13. Gjerde J, Geisler J, Lundgren S, Ekse D, Varhaug JE, Mellgren G, Steen VM, Lien EA (2010) Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer. BMC Cancer 10:313
14. Irvin WJ Jr, Walko CM, Weck KE, Ibrahim JG, Chiu WK, Dees EC, Moore SG, Olajide OA, Graham ML, Canale ST, Raab RE, Corso SW, Peppercorn JM, Anderson SM, Friedman KJ, Ogburn ET, Desta Z, Flockhart DA, McLeod HL, Evans JP, Carey LA (2011) Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study. J Clin Oncol 29(24):3232-3239
15. Gjerde J, Kisanga ER, Hauglid M, Holm PI, Mellgren G, Lien EA (2005) Identification and quantification of tamoxifen and four metabolites in serum by liquid chromatography-tandem mass spectrometry. J Chromatogr A 1082(1):6-14
16. Teunissen SF, Jager NGL, Rosing H, Schinkel AH, Schellens JHM, Beijnen JH (2011) Development and validation of a quantitative assay for the determination of tamoxifen and its five main phase I metabolites in human serum using liquid chroma-tography coupled with tandem mass spectrometry. J Chromatogr B Anal Technol Biomed Life Sci 879(19):1677-1685
17. EMA (2011), Guideline on bioanalytical method validation, European Medicines Agency
18. FDA (2001), Guidance for Industry: Bioanalytical Method Validation, U.S. Food and Drug Administration
19. Jaremko M, Kasai Y, Barginear MF, Raptis G, Desnick RJ, Yu C (2010) Tamoxifen metabolite isomer separation and quantification by liquid chromatography-tandem mass spectrometry. Anal Chem 82(24):10186-10193
20. Teunissen SF, Rosing H, Schinkel AH, Schellens JHM, Beijnen JH (2010) Bioanalytical methods for determination of tamoxifen and its phase I metabolites: a review. Anal Chim Acta 683(1): 21-37